182 related articles for article (PubMed ID: 24000244)
21. Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs.
Zuba D; Sekuła K
Drug Test Anal; 2013 Aug; 5(8):634-45. PubMed ID: 22936468
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
Wood DM; Sedefov R; Cunningham A; Dargan PI
Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
[TBL] [Abstract][Full Text] [Related]
23. The psychoactive drug 25B-NBOMe recapitulates rhabdomyolysis in zebrafish larvae.
Kawahara G; Maeda H; Kikura-Hanajiri R; Yoshida KI; Hayashi YK
Forensic Toxicol; 2017; 35(2):369-375. PubMed ID: 28890736
[No Abstract] [Full Text] [Related]
24. An evaluation of 25B-, 25C-, 25D-, 25H-, 25I- and 25T2-NBOMe via LC-MS-MS: method validation and analyte stability.
Johnson RD; Botch-Jones SR; Flowers T; Lewis CA
J Anal Toxicol; 2014 Oct; 38(8):479-84. PubMed ID: 25217535
[TBL] [Abstract][Full Text] [Related]
25. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.
Gatch MB; Dolan SB; Forster MJ
Behav Pharmacol; 2017 Aug; 28(5):375-385. PubMed ID: 28537942
[TBL] [Abstract][Full Text] [Related]
26. A fatal poisoning involving 25C-NBOMe.
Andreasen MF; Telving R; Rosendal I; Eg MB; Hasselstrøm JB; Andersen LV
Forensic Sci Int; 2015 Jun; 251():e1-8. PubMed ID: 25841303
[TBL] [Abstract][Full Text] [Related]
27. Death after 25C-NBOMe and 25H-NBOMe consumption.
Morini L; Bernini M; Vezzoli S; Restori M; Moretti M; Crenna S; Papa P; Locatelli C; Osculati AMM; Vignali C; Groppi A
Forensic Sci Int; 2017 Oct; 279():e1-e6. PubMed ID: 28893436
[TBL] [Abstract][Full Text] [Related]
28. Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry.
Seo H; Kim IS; Kim YH; Yoo HH; Hong J
Int J Legal Med; 2019 May; 133(3):833-841. PubMed ID: 30090972
[TBL] [Abstract][Full Text] [Related]
29. Gas Chromatography-Mass Spectrometry Method for the Quantitative Identification of 23 New Psychoactive Substances in Blood and Urine.
Nisbet LA; Wylie FM; Logan BK; Scott KS
J Anal Toxicol; 2019 Jun; 43(5):346-352. PubMed ID: 30698723
[TBL] [Abstract][Full Text] [Related]
30. Mass spectrometric properties of N-(2-methoxybenzyl)-2-(2,4,6-trimethoxyphenyl)ethanamine (2,4,6-TMPEA-NBOMe), a new representative of designer drugs of NBOMe series and derivatives thereof.
Shevyrin V; Kupriyanova O; Lebedev AT; Melkozerov V; Eltsov O; Shafran Y; Morzherin Y; Sadykova R
J Mass Spectrom; 2016 Oct; 51(10):969-979. PubMed ID: 27388323
[TBL] [Abstract][Full Text] [Related]
31. Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats.
Wojtas A; Herian M; Skawski M; Sobocińska M; González-Marín A; Noworyta-Sokołowska K; Gołembiowska K
Neurotox Res; 2021 Apr; 39(2):305-326. PubMed ID: 33337517
[TBL] [Abstract][Full Text] [Related]
32. Detection of 25C-NBOMe in Three Related Cases.
Kristofic JJ; Chmiel JD; Jackson GF; Vorce SP; Holler JM; Robinson SL; Bosy TZ
J Anal Toxicol; 2016 Jul; 40(6):466-72. PubMed ID: 27206645
[TBL] [Abstract][Full Text] [Related]
33. Retrospective Demonstration of 25I-NBOMe Acute Poisoning Using Hair Analysis.
Ameline A; Farrugia A; Raul JS; Kintz P
Curr Pharm Biotechnol; 2017; 18(10):786-790. PubMed ID: 29189143
[TBL] [Abstract][Full Text] [Related]
34. 5-HT
Nakamura M; Shintani-Ishida K; Ikegaya H
J Pharmacol Exp Ther; 2018 Nov; 367(2):356-362. PubMed ID: 30206108
[TBL] [Abstract][Full Text] [Related]
35. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS.
Vorce SP; Sklerov JH
J Anal Toxicol; 2004 Sep; 28(6):407-10. PubMed ID: 15516287
[TBL] [Abstract][Full Text] [Related]
36. Schedules of Controlled Substances: Placement of Three Synthetic Phenethylamines Into Schedule I. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2016 Sep; 81(187):66181-4. PubMed ID: 27726316
[TBL] [Abstract][Full Text] [Related]
37. Schedules of Controlled Substances: Extension of Temporary Placement of Three Synthetic Phenethylamines in Schedule I. Final order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2015 Nov; 80(219):70657-9. PubMed ID: 26567439
[TBL] [Abstract][Full Text] [Related]
38. Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule I. Final order.
Drug Enforcement Administration. Department of Justice
Fed Regist; 2013 Nov; 78(221):68716-9. PubMed ID: 24236337
[TBL] [Abstract][Full Text] [Related]
39. MS-Based Molecular Networking of Designer Drugs as an Approach for the Detection of Unknown Derivatives for Forensic and Doping Applications: A Case of NBOMe Derivatives.
Yu JS; Seo H; Kim GB; Hong J; Yoo HH
Anal Chem; 2019 May; 91(9):5483-5488. PubMed ID: 30990678
[TBL] [Abstract][Full Text] [Related]
40. 2C-I-NBOMe, an "N-bomb" that kills with "Smiles". Toxicological and legislative aspects.
Nikolaou P; Papoutsis I; Stefanidou M; Spiliopoulou C; Athanaselis S
Drug Chem Toxicol; 2015 Jan; 38(1):113-9. PubMed ID: 24785196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
